Clinical Cancer Research · 2012 · 68 citations · 51 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyVaccinologyAdjuvant ImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesImmunotherapy For Brain TumorsTherapeutic VaccinesAdjuvanted ImmunotherapyCancer Vaccine T-cell ResponsesGlioblastoma ImmunotherapyNatural Killer-like CellsNatural Regulatory T CellsT Cell-mediated Immune ResponseT-cell Mediated Immune ResponseTherapeutic Cancer Immunization
PURPOSE: The prognosis for patients with glioblastoma multiforme (GBM) remains extremely poor despite recent treatment advances. There is an urgent need to develop novel therapies for this disease. EXPERIMENTAL DESIGN: We used the implantable GL261 murine glioma model to investigate the therapeutic potential of a vaccine consisting of intravenous injection of irradiated whole tumor cells pulsed with the immuno-adjuvant α-galactosylceramide (α-GalCer). RESULTS: Vaccine treatment alone was highly effective in a prophylactic setting. In a more stringent therapeutic setting, administration of one dose of vaccine combined with depletion of regulatory T cells (Treg) resulted in 43% long-term survival and the disappearance of mass lesions detected by MRI. Mechanistically, the α-GalCer component was shown to act by stimulating "invariant" natural killer-like T cells (iNKT cells) in a CD1d-restricted manner, which in turn supported the development of a CD4(+) T-cell-mediated adaptive immune response. Pulsing α-GalCer onto tumor cells avoided the profound iNKT cell anergy induced by free α-GalCer. To investigate the potential for clinical application of this vaccine, the number and function of iNKT cells was assessed in patients with GBM and shown to be similar to age-matched healthy volunteers. Furthermore, irradiated GBM tumor cells pulsed with α-GalCer were able to stimulate iNKT cells and augment a T-cell response in vitro. CONCLUSIONS: Injection of irradiated tumor cells loaded with α-GalCer is a simple procedure that could provide effective immunotherapy for patients with high-grade glioma.
51
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
CD1d-Restricted and TCR-Mediated Activation of V <sub>α</sub> 14 NKT Cells by Glycosylceramides
Tetsu Kawano, Junqing Cui, Yasuhiko Koezuka et al. · Science · 1997 · 2.4K citations
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Sergio A. Quezada, Tyler R. Simpson, Karl S. Peggs et al. · The Journal of Experimental Medicine · 2010 · 887 citations · Full text
Life Sciences, Immunology, Oncology +17